Insulin Detemir (CAT#: TP-005CL)
Insulin detemir is a long-acting human insulin analogue used to maintain basal levels of insulin in diabetic individuals. It is produced using recombinant DNA technology in yeast cells. This insulin analogue has a 14-C fatty acid, myristic acid, bound to the lysine amino acid at position B29. The myristoyl side chain increases self-association and albumin binding. This along with slow systemic absorption from the injection site prolongs distribution of the hormone into tissues and results in a long duration of action. Novo Nordisk markets insulin detemir under the trade name Levemir.
Specifications
- Classify
- Protein therapeutics replacing a protein that is deficient or abnormal: Endocrine disorders (hormone deficiencies)
- Therapeutic
- Insulin detemir; insulin glargine
- Trade Name
- Levemir (Detemir), Lantus (Glargine)
- Function
- Insulin analogues with slower onset of action and longer duration of action
- Examples of clinical use
- Diabetes mellitus
References
- Synonyms
- Insulin detemir, Insulin detemir recombinant, Levemir, Levemir flexpen, Levemir innolet, Levemir penfill, NN-304
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TP-005CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.